이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

TAVI in LOW RISK in the REAL WORLD (TAVI IN LOW R)

2026년 5월 18일 업데이트: Centro Cardiologico Monzino
The primary objective is to assess all-cause mortality, the occurrence of stroke, or rehospitalization for cardiovascular causes in low-risk "all-comers" patients following percutaneous aortic valve replacement

연구 개요

상태

완전한

상세 설명

Severe aortic stenosis is the most common valvular heart disease worldwide. Its prevalence increases with age and is estimated to affect approximately 2% of the population aged 70-80 and as many as 9% of adults over 80 years of age.¹ Given the progressive aging of the population and the ever-increasing life expectancy, its prevalence will continue to rise, representing not only a topic of scientific interest but also a significant public health issue. In the past, the treatment of severe aortic stenosis was strictly the domain of cardiac surgery, and the gold standard was aortic valve replacement via open-heart surgery. In 2002, however, in an effort to offer a compassionate treatment option to patients considered high-risk or even ineligible for traditional surgery, transcatheter aortic valve replacement (TAVI) was introduced. The PARTNER study was the first randomized trial to evaluate the use of a balloon-expandable valve (Sapien - Edwards). The study consisted of two cohorts: Cohort A, comprising patients at high surgical risk, demonstrated that TAVI was non-inferior to SAVR in terms of 1-year all-cause mortality.

And a second cohort, Cohort B, which enrolled patients who were not considered suitable candidates for surgical aortic valve replacement (SAVR) and demonstrated a reduction in the rate of all-cause mortality or rehospitalization with transcatheter aortic valve implantation (TAVI) compared with standard medical therapy.² The efficacy and safety of transcatheter aortic valve replacement were quickly recognized by the ESC/EACTS and ACC/AHA, which incorporated this technique into their guidelines in 2012 and 2014, respectively. TAVI was in fact recommended as a Class I recommendation for patients ineligible for cardiac surgery and as a Class IIA recommendation for high-risk patients. At the same time, the CoreValve Extreme Risk Pivotal and CoreValve US Pivotal studies demonstrated the safety and efficacy of a self-expanding valve in the treatment of aortic stenosis (CoreValve - Medtronic); and in the second study, even its superiority over traditional surgery.

Since then, several studies have been conducted to demonstrate the safety and efficacy (non-inferiority) of TAVI compared to SAVR, even in intermediate-risk patients, including PARTNER 2 (which used a second-generation Sapien XT valve) and SURTAVI (CoreValve and Evolut R). Once again, guidelines were not long in coming, and in 2017, the ESC/EACTS classified the use of TAVI in patients with increased risk (intermediate or high) as Class I. Two further studies, PARTNER 3 and Evolut Low Risk, subsequently demonstrated the non-inferiority of TAVI compared to SAVR, thereby securing approval in Europe and the United States for use in low-risk patients. These valves have distinguished themselves by achieving excellent results across various outcomes in low-risk patients. In fact, Sapien 3 demonstrated superior results in terms of 1-year mortality and stroke rates and a lower need for pacemaker implantation compared to Evolut, which, however, achieved better hemodynamic performance within its own studies. Currently, registries showing TAVI outcomes in real-world patients are few and limited; therefore, it is important to assess whether data on outcomes in low-risk all-comers outside of trial settings align with trial results.

Patients included in the retrospective part of the study will be enrolled from January 2021 through September 2024 and will account for approximately two-thirds of the patients enrolled in the CCM.

Patients included in the prospective part of the study will be enrolled from October 2024 through August 2025.

For all patients deemed eligible, data will be collected regarding the screening/baseline visit, procedural data, discharge, and 12-month follow-up

연구 유형

관찰

등록 (실제)

650

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • BS
      • Brescia, BS, 이탈리아, 25124
        • Fondazione Poliambulanza Istituto Ospedaliero, Unità Emodinamica

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

샘플링 방법

비확률 샘플

연구 인구

Consecutive patients with symptomatic severe aortic valve stenosis and low surgical risk-defined as an STS-PROM score (Society of Thoracic Surgeons Predicted Risk of Mortality for isolated SAVR) of less than 4% and no major organ damage-who were treated with TAVI.

설명

Inclusion Criteria:

  • Patients aged 18 years or older
  • Patients with severe symptomatic aortic valve stenosis undergoing TAVI.
  • Patients considered to be at low surgical risk, defined as an STS-PROM (Society of Thoracic Surgeons Predicted Risk of Mortality for isolated SAVR) score of less than 4% and no major organ damage.

Exclusion Criteria:

  • Patients who required emergency aortic valve replacement for any reason
  • Need for conversion to SAVR during the procedure
  • Patients who refused to consent to participate in the study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
Patients with symptomatic severe aortic valve stenosis
Consecutive patients with symptomatic severe aortic valve stenosis and low surgical risk-defined as an STS-PROM score (Society of Thoracic Surgeons Predicted Risk of Mortality for isolated SAVR) of less than 4% and no major organ damage-who were treated with TAVI.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
All-cause mortality
기간: Up to 12 months
Up to 12 months
Occurrence of stroke
기간: Up to 12 months
Up to 12 months
Rehospitalization for cardiovascular causes
기간: Up to 12 months
Up to 12 months

2차 결과 측정

결과 측정
기간
Occurrence of major or minor bleeding
기간: Up to 12 months
Up to 12 months
Implantation of a permanent pacemaker
기간: Up to 12 months
Up to 12 months
Development of paroxysmal or permanent atrial fibrillation
기간: Up to 12 months
Up to 12 months
Infectious causes requiring prolonged monitoring in the hospital
기간: Up to 12 months
Up to 12 months
Presence of significant paravalvular or intravalvular regurgitation
기간: Up to 12 months
Up to 12 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 12월 13일

기본 완료 (실제)

2025년 8월 24일

연구 완료 (실제)

2025년 8월 24일

연구 등록 날짜

최초 제출

2026년 4월 15일

QC 기준을 충족하는 최초 제출

2026년 5월 18일

처음 게시됨 (실제)

2026년 5월 26일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 5월 26일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 5월 18일

마지막으로 확인됨

2026년 4월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다